Our people
Innovators in drug development
Our team comprises drug inventors, scientists, and business leaders with decades of expertise in pharmaceutical research, drug development, clinical trials, business transactions, and product commercialization. We operate with a consciously lean, efficient model, that minimizes overhead costs and maximizes our adaptability.
We conduct discovery and critical in vitro and most in vivo studies in house and collaborate with partners expert in machine-based library analyses, medicinal and computational chemistry, high-throughput screening, chemical syntheses, regulatory matters, and to access specialized technologies and independently validate critical findings. We are also assisted by distinguished expert scientific and clinical advisors.
As SHY moves closer to the clinic and expands its number of development programs the breadth of its in-house expertise and numbers of scientists will need to grow.
Meet our team
Dr. Yaron Hadari
Co-founder, CEO, & CSO
SHY Therapeutics
Michael Schmertzler
Co-founder & Executive Chairman of the Board
SHY Therapeutics
Dr. Mark Mitchnick
Co-founder & Director
SHY Therapeutics
Stanley Choy
Co-founder
SHY Therapeutics
Theresa Williams
Head of Medicinal Chemistry
Wise Consulting, LLC
Sarah Recchio
COO
SHY Therapeutics
Our values
SHY has a patient-centric mission and a culture that values creativity, open-mindedness, constant learning, rigor, independent initiative, kindness, respect, and fairness.
We set high standards for ourselves and our collaborators to ensure excellence in all we do.
